Across 54 CTIS Phase II–III records, CKD and kidney failure trials show two different operational patterns: broad dialysis-network deployment in Phase III and smaller nephrology specialist clusters in Phase II. The most repeated site/legal-site names were dialysis platforms and high-volume academic nephrology centers, while large country allocations concentrated around Spain, Germany, Austria, Bulgaria, Denmark, France, Greece, Italy, and Poland.
The top 10 site/legal-site anchors were ranked by recorded appearances in the available geography records. TritonLife Dializis Center Kft. led with 5 recorded site entries, followed by First Dialysis Services Bulgaria EAD with 3. Eight other recurring centers or legal-site names appeared 2 times each.
The site pattern is not dominated by one academic mega-center. Instead, CKD and kidney failure development relies on distributed nephrology, diabetes-kidney, and dialysis infrastructure, especially where trials target hemodialysis, renal anemia, hypertension, diabetes-related CKD, or kidney failure populations.
Of the 54 included records, 33 were Phase III and 21 were Phase II. Phase III therefore represented 61.1% of the dataset, while Phase II represented 38.9%.
The Phase III tilt means site strategy is heavily shaped by execution scale, not just exploratory nephrology science. This explains why dialysis groups, multicenter national site lists, and countries with many smaller nephrology centers appear prominently.
The largest visible country-level participant allocations were Germany with 124 and 64 participants in renal anemia Phase III records, Denmark with 260 participants in one Phase II CKD record, Austria with 220, Spain with 150, France with 100, and Greece with 100.
Country selection appears indication-dependent: dialysis and renal anemia studies can concentrate participants in fewer countries, while diabetes-related CKD and hypertension-linked CKD studies tend to use broader multi-country networks.
The CKD/kidney failure cohort contains several recurring clinical contexts: generic chronic kidney disease, end-stage renal/kidney disease, hemodialysis or dialysis-dependent kidney failure, renal anemia/anemia of CKD, CKD with hypertension, CKD with diabetes or obesity, kidney transplantation, and CKD with cardiovascular disease.